Drug Discovery World

OCTOBER 19, 2022

Ashley Rein , Global Market Manager for Topical Drug Delivery at Lubrizol Life Science Health (LLS Health), explains how by using mucoadhesive drug delivery, developers can bring novel drugs to market and maximise the efficacy of pre-existing APIs. . Consider drug delivery systems early on .

Drug Delivery 52

Drug Delivery Drugs Drug Delivery Systems Development 52

Drug Discovery World

AUGUST 4, 2022

It may seem counterintuitive to spend time and money on planning for containment and delivery systems for a drug in the earliest stages of discovery when the chances of that molecule making it to market are still quite low. Food and Drug Administration (FDA) for approval of drug-device combinations.

Containment 52

Containment Development Drugs Production 52

XTalks

JANUARY 18, 2023

Ayesha also talked about the FDA approval of AstraZeneca’s asthma inhaler Airsupra, the first-in-class drug that contains both a beta agonist and corticosteroid. Subscribe to the Xtalks Life Science Podcast to never miss a new episode. Hear more about the new subvariant and why scientists are keeping a close eye on it.

Life Science 52

Life Science FDA Approval Containment Scientist 52

XTalks

JUNE 14, 2023

XTALKS WEBINAR: Drug Delivery — Evaluating Off-The-Shelf and Novel Drug Delivery Solutions Live and On-Demand: Tuesday, July 11, 2023, at 1pm EDT (10am PDT) Register for this free webinar to learn about important tradeoffs when considering an off-the-shelf (OTS) drug delivery platform vs. novel development.

Gene Silencing 97

Gene Silencing Drug Delivery FDA Approval RNA 97

Drug Discovery World

AUGUST 9, 2023

The life sciences sector has seen significant M&A activity over the last few weeks. DDW’s Diana Spencer provides an overview. We are thrilled to announce BioIVT’s acquisition of PrecisionMed.

Drugs 52

Drugs Drug Delivery Systems Drug Delivery Life Science 52

XTalks

JANUARY 17, 2023

The US Food and Drug Administration (FDA) granted approval to AstraZeneca’s Airsupra (albuterol/budesonide), formerly known as PT027, for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of asthma attacks in individuals aged 18 years and older who have asthma.

FDA Approval 97

FDA Approval Containment Allergies Drugs 97

The Pharma Data

NOVEMBER 4, 2020

CorpCann is a Norwegian-based international investment and consulting firm focused on European and North American opportunities in the life science, nutraceutical, aquaculture and energy industries. XPhyto is also pleased to announce a strategic European advisor engagement with CorpCann AS (“CorpCann”).

Drug Delivery 40

Drug Delivery Production Manufacturing Life Science 40